section name header

Pronunciation

mid-AY-zoe-lam

Classifications

Therapeutic Classification: antianxiety agents, anticonvulsants, sedative/hypnotics

Pharmacologic Classification: benzodiazepines

Indications

IM:

BEERS REMS, High Alert


Action

  • Acts at many levels of the CNS to produce generalized CNS depression.
  • Effects may be mediated by GABA, an inhibitory neurotransmitter.
Therapeutic effects:
  • Short-term sedation.
  • Postoperative amnesia.
  • Termination of seizure activity.

Pharmacokinetics

Absorption: Rapidly absorbed following oral and nasal administration; undergoes substantial intestinal and first-pass hepatic metabolism. Well absorbed following IM administration; IV administration results in complete bioavailability.

Distribution: Crosses the blood-brain barrier and placenta; excreted in breast milk.

Protein Binding: 97%.

Metabolism/Excretion: Almost exclusively metabolized by the liver by the CYP3A4 isoenzyme, resulting in conversion to hydroxymidazolam, an active metabolite, and 2 other inactive metabolites; metabolites are excreted in urine.

Half-Life: Preterm neonates: 2.6–17.7 hr; Neonates: 4–12 hr; Children: 3–7 hr; Adults: 2–6 hr ( in renal impairment, HF, or cirrhosis).

Time/Action Profile

(sedation)

ROUTEONSETPEAKDURATION
IN5 min10 min30–60 min
IM15 min30–60 min2–6 hr
IV1.5–5 minrapid2–6 hr



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: arrhythmias, CARDIAC ARREST

Derm: rash

EENT: blurred vision

GI: hiccups, nausea, vomiting

Local: phlebitis at IV site, pain at IM site

Neuro: agitation, drowsiness, excess sedation, headache, SUICIDAL THOUGHTS

Resp: APNEA, bronchospasm, cough, LARYNGOSPASM, RESPIRATORY DEPRESSION

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Preoperative Sedation/Anxiolysis/Amnesia

Conscious Sedation for Short Procedures

Status Epilepticus

Seizure Clusters

Induction of Anesthesia (Adjunct)

Sedation in Critical Care Settings

Availability

(Generic available)
  • Oral syrupcherry flavor: 2 mg/mL
  • Nasal spray (Nayzilam): 5 mg/0.1 mL single-dose unit
  • Premixed infusion: 100 mg/100 mL 0.8% NaCl; 50 mg/50 mL 0.9% NaCl; 100 mg/100 mL 0.9% NaCl
  • Solution for injection: 1 mg/mL; 5 mg/mL

Assessment

  • Assess level of sedation and level of consciousness during and for 2–6 hr following administration.
  • Monitor BP, HR, and respiratory rate continuously during administration, especially if coadministering opioid analgesics. Oxygen and resuscitative equipment should be immediately available during IV administration.
  • Assess risk for addiction, abuse, or misuse before starting and periodically during therapy.

Toxicity and Overdose:

  • If overdose occurs, monitor BP, HR, and respiratory rate continuously. Maintain patent airway and assist ventilation as needed. If hypotension occurs, treatment includes IV fluids, repositioning, and vasopressors.
    • The effects of midazolam can be reversed with flumazenil.

Implementation

  • Accidental overdose of oral midazolam syrup in children has resulted in serious harm or death. Do not accept orders prescribed by volume (5 mL or 1 teaspoon); instead, request dose be expressed in milligrams. Have second practitioner independently check original order and dose calculations. Midazolam syrup should only be administered by health care professionals authorized to administer conscious sedation.

  • Supervise ambulation and transfer of patients after administration. Two side rails should be raised and call bell within reach at all times.
  • Gradually taper to discontinue or the dose to risk of withdrawal reactions, seizure frequency, and status epilepticus. If withdrawal symptoms develop, pause taper or dose to previous tapered dose level; dose more slowly. Some patients may require longer tapering period (wks to >12 mo).
  • PO: To use the Press-in Bottle Adaptor, remove the cap and push bottle adaptor into neck of bottle. Close bottle tightly with cap. Solution is a clear red to purplish-red cherry-flavored syrup. Then remove cap and insert tip of oral dispenser in bottle adaptor. Push the plunger completely down toward tip of oral dispenser and insert firmly into bottle adaptor. Turn entire unit (bottle and oral dispenser) upside down. Pull plunger out slowly until desired amount of medication is withdrawn into oral dispenser. Turn entire unit right side up and slowly remove oral dispenser from the bottle. Tip of dispenser may be covered with tip of cap until time of use. Close bottle with cap after each use.
    • Dispense directly into mouth. Do not mix with any liquid prior to dispensing.
  • Administer 1 spray into one nostril. If no response to initial dose after 10 min, may administer 1 spray into other nostril.

  • IM: Administer IM doses deep into mid-outer thigh (vastus lateralis muscle), maximum concentration 1 mg/mL. Solution is clear, colorless to light yellow. Do not administer solutions that are discolored or contain particulate matter.

IV Administration:

  • Diluent: Administer undiluted or diluted with D5W or 0.9% NaCl.Concentration: Undiluted: 1 mg/mL or 5 mg/mL. Diluted: 0.03–3 mg/mL.

  • Rate: Administer slowly over at least 2–5 min. Titrate dose to patient response. Rapid injection, especially in neonates, has caused severe hypotension.
  • Diluent: Dilute with 0.9% NaCl or D5WConcentration: 0.5–1 mg/mL.

  • Rate: Based on patient's weight (see Route/Dosage section). Titrate to desired level of sedation. Assess sedation at regular intervals and adjust rate up or down by 25–50% as needed. Dose should also be by 10–25% every few hrs to find minimum effective infusion rate, which prevents accumulation of midazolam and provides more rapid recovery upon termination.

Patient/Family Teaching

Evaluation/Desired Outcomes

  • Sedation during and amnesia following surgical, diagnostic, and radiologic procedures.
  • Sedation and amnesia for mechanically ventilated patients in a critical care setting.
  • Termination of seizure activity.

US Brand Names

Nayzilam, Seizalam, Versed

Contr. Subst. Schedule

Schedule IV (C-IV)

Code

NDC Code